Moleculin Biotech Stock Forecast, Price & News

-0.09 (-2.80 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume115,777 shs
Average Volume257,086 shs
Market Capitalization$88.73 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MBRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

Moleculin Biotech logo

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions

What stocks does MarketBeat like better than Moleculin Biotech?

Wall Street analysts have given Moleculin Biotech a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Moleculin Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Moleculin Biotech's next earnings date?

Moleculin Biotech is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Moleculin Biotech

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) issued its earnings results on Tuesday, May, 11th. The company reported ($0.20) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.03.
View Moleculin Biotech's earnings history

How has Moleculin Biotech's stock been impacted by COVID-19?

Moleculin Biotech's stock was trading at $3.0306 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MBRX shares have increased by 2.9% and is now trading at $3.12.
View which stocks have been most impacted by COVID-19

When did Moleculin Biotech's stock split? How did Moleculin Biotech's stock split work?

Shares of Moleculin Biotech reverse split on the morning of Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of Moleculin Biotech stock prior to the reverse split would have 17 shares after the split.

Who are Moleculin Biotech's key executives?

Moleculin Biotech's management team includes the following people:
  • Mr. Walter V. Klemp, Founder, Chairman, Pres & CEO (Age 61, Pay $778.14k)
  • Mr. Jonathan P. Foster, Exec. VP & CFO (Age 57, Pay $568.61k)
  • Dr. Donald H. Picker, Chief Scientific Officer (Age 75, Pay $438.16k)
  • Dr. Waldemar Priebe Ph.D., Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Robert C. Shepard FACP, M.D., F.A.C.P., Chief Medical Officer of Annamycin (Age 69)
  • Dr. Sandra L. Silberman, Chief Medical Officer of New Products (Age 65)
  • Ms. Jacqueline Northcut, Consultant (Age 59)
  • Mr. Louis Ploth Jr., Independent Advisor (Age 67)

Who are some of Moleculin Biotech's key competitors?

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

How do I buy shares of Moleculin Biotech?

Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Moleculin Biotech's stock price today?

One share of MBRX stock can currently be purchased for approximately $3.12.

How much money does Moleculin Biotech make?

Moleculin Biotech has a market capitalization of $88.73 million. The company earns $-17,350,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Moleculin Biotech have?

Moleculin Biotech employs 10 workers across the globe.

What is Moleculin Biotech's official website?

The official website for Moleculin Biotech is

Where are Moleculin Biotech's headquarters?

Moleculin Biotech is headquartered at 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The company can be reached via phone at 713-300-5160 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.